A detailed history of Ubs Group Ag transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Ubs Group Ag holds 29,240 shares of ALXO stock, worth $53,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,240
Previous 15,453 89.22%
Holding current value
$53,509
Previous $93,000 43.01%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.81 - $8.13 $24,954 - $112,088
13,787 Added 89.22%
29,240 $53,000
Q2 2024

Aug 13, 2024

SELL
$5.84 - $17.56 $79,546 - $239,184
-13,621 Reduced 46.85%
15,453 $93,000
Q1 2024

May 13, 2024

SELL
$10.95 - $16.79 $20,958 - $32,136
-1,914 Reduced 6.18%
29,074 $324,000
Q4 2023

Feb 09, 2024

BUY
$4.81 - $15.38 $95,209 - $304,431
19,794 Added 176.83%
30,988 $461,000
Q3 2023

Nov 09, 2023

SELL
$4.19 - $7.35 $4,893 - $8,584
-1,168 Reduced 9.45%
11,194 $53,000
Q2 2023

Aug 11, 2023

BUY
$4.37 - $9.56 $10,134 - $22,169
2,319 Added 23.09%
12,362 $92,000
Q1 2023

May 12, 2023

BUY
$4.52 - $11.71 $12,660 - $32,799
2,801 Added 38.68%
10,043 $45,000
Q4 2022

Feb 08, 2023

BUY
$9.51 - $12.95 $68,871 - $93,783
7,242 New
7,242 $81,000
Q2 2022

Aug 10, 2022

SELL
$5.89 - $19.46 $506,964 - $1.67 Million
-86,072 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $105,459 - $170,435
-7,726 Reduced 8.24%
86,072 $1.46 Million
Q4 2021

Feb 14, 2022

BUY
$21.49 - $74.4 $1.86 Million - $6.44 Million
86,532 Added 1190.92%
93,798 $2.02 Million
Q3 2021

Nov 15, 2021

BUY
$52.51 - $80.91 $132,745 - $204,540
2,528 Added 53.36%
7,266 $537,000
Q2 2021

Aug 13, 2021

SELL
$52.2 - $75.23 $741,762 - $1.07 Million
-14,210 Reduced 74.99%
4,738 $259,000
Q1 2021

May 12, 2021

BUY
$62.84 - $87.68 $1.19 Million - $1.66 Million
18,898 Added 37796.0%
18,948 $1.4 Million
Q4 2020

Feb 11, 2021

BUY
$34.11 - $112.26 $1,705 - $5,613
50 New
50 $4,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $74.6M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.